As India marks World MSME Day 2026, industry leaders from the pharmaceutical sector have called for policy reforms to improve the competitiveness of small and medium drug manufacturers. They say geopolitical tensions, rising input costs, supply chain disruptions and tightening regulatory requirements are placing disproportionate pressure on MSME pharmaceutical companies.
India's pharmaceutical sector, often described as the “pharmacy of the world”, has built a strong global presence in generic medicines and vaccines. The industry reported a turnover of around Rs 2.25 lakh crore in FY25, while exports touched $30.5 billion, making a resilient MSME ecosystem increasingly important amid global supply chain disruptions.
